News Home
Quick Bites
News Archive
News Channel
Special Features
On AirNewsClassical
School Closings
WKSU Support
Funding for WKSU is made possible in part through support from the following businesses and organizations.

Meaden & Moore



For more information on how your company or organization can support WKSU, download the WKSU Media Kit.

(WKSU Media Kit PDF icon )

Donate Your Vehicle to WKSU

Programs Schedule Make A Pledge Member BenefitsFAQ/HelpContact Us
Health and Medicine

Exploradio: Breast cancer vaccine targets 'retired' protein
A novel approach to cancer prevention teaches the body's immune system to target tumors, but a breast cancer vaccine may be too far outside the box for mainstream funders
This story is part of a special series.

Reporter / Host
Jeff St. Clair
October is breast cancer awareness month. But a Cleveland Clinic researcher has had a hard time attracting research dollars. That is, until local donors stepped in to fund Vincent Tuohy's idea for a breast cancer vaccine.
Courtesy of Richard Taylor Flickr CC
Download (WKSU Only)
In The Region:

A Cleveland scientist has devised a novel approach to treating breast cancer.

But in this week' Exploradio, WKSU' Jeff St.Clair reports that the hardest part of Vincent Tuohy' work has been getting fellow researchers to believe cancer prevention is possible.


Exploradio: Breast cancer vaccine

Other options:
Windows Media / MP3 Download (4:18)

Mane of white hair inspires retired proteins

Cleveland Clinic researcher Vincent Tuohy’s inspiration for a breast cancer vaccine came from an unlikely source, "a man with a beautiful mane of white hair.”

It was a true eureka moment, according to Tuohy, because while admiring the man's full head of hair he came up with his, "retired protein hypothesis.”

Tuohy realized that as we age, specific tissues, like the pigment cells in the man’s hair, stop making certain proteins.  “They become retired,” according to Tuohy.

He theorized that if abnormal tissues like tumors produce these retired proteins, they could be targeted by the body's own immune system.

Having spent a carrier studying auto-immune diseases, Tuohy knew T-cells could be trained to recognized retired proteins that often occur in tumor cells, but rarely in healthy tissues, “That’s what cancer vaccines are, they’re auto-immune vaccines.”

He soon found a protein in lactating breast tissue that is not expressed in post-menopausal women, or in women without children.  But breast tumors in the mouse models Tuohy studied do express it.  It’s called alpha-lactalbumin.


Targeting alph-lactalbumin in the lab

In his lab, Tuohy gives the fifteen second version of how the lactalbumin protein is made while grad student Justin Johnson shows the proper technique to make vaccines to test in mice. Johnson says it takes around an hour to to get it mixed right.

“We take a gene, we cut the gene, we put it in the vector, we have the vector stuck in the bacteria, the bacteria grow, they make the protein, we purify the protein from the bacteria, and that’s our target protein.”

 The lactalbumin vaccine was tested on mice bred to develop breast cancer at an early age.  Tuohy says the results in the vaccinated mice were dramatic, "none of the mice had tumors at 10 months of age."  But he says in the control mice that were not immunized with the protein, "100 percent of them had tumors.”

The discovery gained international attention in 2010 when Tuohy first published his results in the journal Nature Medicine.  But not all of it positive.


“There’s been a lot of pushback.”

Tuohy feels he got the cold shoulder from the cancer research community. He says his idea of targeting retired proteins in tumors was out of their box, "because nobody believed you could make a vaccine that could prevent breast cancer," and he was an from another field.

Tuohy had spent his career studying auto-immune diseases like MS. In his prior research he harnessed the immune system to attack retired cells in other organ systems.  But Tuohy's outsider status has made it hard for him to raise money from major breast cancer funders.  He’s 0-15 in grant requests in the three years since his paper was published.  He says, "I’m doing the best work of my career and I get turned down.

Shield Biotech leads clinical trials

But local supporters, some anonymous, have stepped up to cover the $6 million needed to begin testing Tuohy’s breast cancer vaccine in humans.  Last month the Cleveland Clinic’s business creation arm launched Shield Biotech to manage clinical trials that could cost upwards of $100 million over the next decades.

Tuohy sees his work as the first step in filling a hole in our approach to age related diseases, the lack of a vaccine program for adults.  "It’s ridiculous,” says Tuohy.

He says the research establishment is so focused on cancer treatment, that the idea of cancer prevention has yet to take hold.

“The hardest thing I’ve had to do is not develop the vaccine, [but] convince people that what they thought was impossible is possible.”

Tuohy and his team at the Cleveland Clinic’s Lerner Research Institute are hoping their breast cancer vaccine will pave the way for treating and preventing other diseases. He’s currently developing vaccines targeting retired proteins in prostate, ovarian and other cancers.

(Click image for larger view.)

Add Your Comment


E-mail: (not published, only used to contact you about your comment)


Page Options

Print this page

E-Mail this page / Send mp3

Share on Facebook

Support for Exploradio
provided by:

Stories with Recent Comments

Backers of legalizing marijuana in Ohio promise to be back in 2016
We should be aloud to grow more than 4 plants and not have to register with the state considering it will be a free market.

Akron says it's had no second thoughts about welcoming refugees
What business does Councilman Neal own on North Hill? I'd love to support him. I am so glad to have the refugees in our neighborhood. I have lived here for 25 ...

Scarborough says the University of Akron is trying to rebuild relationships
In order for the University of Akron to grow and become a desirable place for students across Ohio and elsewhere, it must address the crime problem in the Akron...

Ohio Sen. Cliff Hite wants to end pay-to-play sports fees at Ohio's schools
You can bet Hite and Husted will also rush to the rescue of the Academic Challenge team, the speech-and-debate squad, the Science Olympians and the chess club. ...

Ohio lawmakers consider new gun bills
States that have gun restrictions/cities have reduced gun violence is false. CHICAGO has some of the toughest gun laaws/restrictions but yet fun violence is off...

Cleveland's public transit system considers fare increase for 2016
I work with individuals with disabilities. Yes some of my folks need more help than the average person. As a whole, the group I work with however can manuver ju...

Community group sues to re-open part of Wadsworth hospital
My father was part of the founding group of citizens which started the "new" Wadsworth/Rittman Hospital. For some reason the leadership for the future of the ho...

The Cleveland Museum of Art presents painters who loved their gardens
brilliant masterpiece, Greetings from

Ohio Sen. Tom Patton proposes bill for firefighter cancer benefits
Thank you Senator Patton. On behalf of all of those who love our firefighters; we appreciate that someone is standing up for them and their continued health. ??...

Copyright © 2015 WKSU Public Radio, All Rights Reserved.

In Partnership With:

NPR PRI Kent State University

listen in windows media format listen in realplayer format Car Talk Hosts: Tom & Ray Magliozzi Fresh Air Host: Terry Gross A Service of Kent State University 89.7 WKSU | NPR.Classical.Other smart stuff. NPR Senior Correspondent: Noah Adams Living on Earth Host: Steve Curwood 89.7 WKSU | NPR.Classical.Other smart stuff. A Service of Kent State University